{"id":59424,"date":"2024-05-24T07:03:27","date_gmt":"2024-05-24T05:03:27","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\/"},"modified":"2024-05-24T07:03:27","modified_gmt":"2024-05-24T05:03:27","slug":"innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\/","title":{"rendered":"Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<b><i>Top line results of TELLOMAK Phase 2 trial in mycosis fungoides confirming promising clinical activity of lacutamab<\/i><\/b><\/li>\n<li>\n<b><i>Two posters on IPH6501, Innate\u2019s second generation ANKET<sup>\u00ae<\/sup>, for the treatment of relapsed\/refractory CD20-expressing B-cell Non-Hodgkin&#8217;s Lymphoma<\/i><\/b><\/li>\n<li>\n<b><i>AstraZeneca to present poster on updated results for monalizumab from Phase 2 stage III unresectable NSCLC trial<\/i><\/b><\/li>\n<li>\n<b><i>Monalizumab SCLC Phase 2 MOZART trial poster<\/i><\/b><\/li>\n<\/ul>\n<p>MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/ANKET?src=hash\" target=\"_blank\" rel=\"noopener\">#ANKET<\/a>&#8211;Regulatory News:<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20240523437811\/en\/1245155\/4\/INNATEvertnoirDS.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20240523437811\/en\/1245155\/22\/INNATEvertnoirDS.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20240523437811\/en\/1245155\/4\/INNATEvertnoirDS.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20240523437811\/en\/1245155\/21\/INNATEvertnoirDS.jpg\"><\/a><\/p>\n<p>\nInnate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201c<b>Innate<\/b>\u201d or the \u201c<b>Company<\/b>\u201d) announced today that five abstracts with Innate\u2019s drug candidates have been accepted for the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place May 31-June 4, 2024 in Chicago, Illinois.<\/p>\n<p>\n<b>ASCO abstract details:<\/b><\/p>\n<p>\n<b><span class=\"bwuline\">Lacutamab<\/span><\/b><\/p>\n<p class=\"bwmarginl1\">\n<b>Abstract: <\/b><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmeetings.asco.org%2Fabstracts-presentations%2F232718&amp;esheet=54014712&amp;newsitemid=20240523437811&amp;lan=en-US&amp;anchor=7082&amp;index=1&amp;md5=95b8338249a014bdcd5ef6186baa8426\" rel=\"nofollow noopener\" shape=\"rect\">7082<\/a><br \/><b>Abstract Title:<\/b> Lacutamab in patients with relapsed and\/or refractory mycosis fungoides: results from the TELLOMAK Phase 2 trial<br \/>\n<br \/><b>First Author:<\/b> Pierluigi Porcu<br \/>\n<br \/><b>Session Type: <\/b>Poster Session<br \/>\n<br \/><b>Session Title: <\/b>Hematologic Malignancies\u2014Lymphoma and Chronic Lymphocytic Leukemia<br \/>\n<br \/><b>Session Date and Time: <\/b>Monday June 3, 2024 \u2013 9:00 AM \u2013 12:00 PM<\/p>\n<p>\n<b><span class=\"bwuline\">IPH6501<\/span><\/b><\/p>\n<p class=\"bwmarginl1\">\n<b>Abstract: <\/b><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmeetings.asco.org%2Fabstracts-presentations%2F238190&amp;esheet=54014712&amp;newsitemid=20240523437811&amp;lan=en-US&amp;anchor=TPS7095&amp;index=2&amp;md5=959d6bf34f32a3b0e57779dc57bf3baf\" rel=\"nofollow noopener\" shape=\"rect\">TPS7095<\/a><br \/><b>Abstract Title:<\/b> A Phase 1\/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Patients With Relapsed and\/or Refractory CD20-expressing Non-Hodgkin Lymphoma<br \/>\n<br \/><b>First Author:<\/b> Lorenzo Falchi<br \/>\n<br \/><b>Session Type: <\/b>Poster Session<br \/>\n<br \/><b>Session Title: <\/b>Hematologic Malignancies\u2014Lymphoma and Chronic Lymphocytic Leukemia<br \/>\n<br \/><b>Session Date and Time: <\/b>Monday June 3, 2024 \u2013 9:00 AM \u2013 12:00 PM<\/p>\n<p class=\"bwmarginl1\">\n<b>Abstract: <\/b><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmeetings.asco.org%2Fabstracts-presentations%2F232696&amp;esheet=54014712&amp;newsitemid=20240523437811&amp;lan=en-US&amp;anchor=7030&amp;index=3&amp;md5=581cd2eb80163c1d9ec7a802393fe342\" rel=\"nofollow noopener\" shape=\"rect\">7030<\/a><br \/><b>Abstract Title:<\/b> Preclinical assessment of IPH6501, a first-in-class IL2v-armed tetraspecific NK Cell Engager directed against CD20 for R\/R B-NHL, in comparison to a CD20-targeting T Cell Engager<br \/>\n<br \/><b>First Author:<\/b> Olivier Demaria<br \/>\n<br \/><b>Session Type: <\/b>Poster Session<br \/>\n<br \/><b>Session Title: <\/b>Hematologic Malignancies\u2014Lymphoma and Chronic Lymphocytic Leukemia<br \/>\n<br \/><b>Session Date and Time: <\/b>Monday June 3, 2024 \u2013 9:00 AM \u2013 12:00 PM<\/p>\n<p>\n<b><span class=\"bwuline\">Monalizumab (partnered with AstraZeneca)<\/span><\/b><\/p>\n<p class=\"bwmarginl1\">\n<b>Abstract: <\/b><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmeetings.asco.org%2Fabstracts-presentations%2F232386&amp;esheet=54014712&amp;newsitemid=20240523437811&amp;lan=en-US&amp;anchor=8046&amp;index=4&amp;md5=0fd1817db6352e7a9bc64702cbd75da5\" rel=\"nofollow noopener\" shape=\"rect\">8046<\/a><br \/><b>Abstract Title:<\/b> Updated results from COAST, a phase 2 study of durvalumab (D) \u00b1 oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC)<br \/>\n<br \/><b>First Author:<\/b> Charu Aggarwal<br \/>\n<br \/><b>Session Type: <\/b>Poster Session<br \/>\n<br \/><b>Session Title: <\/b>Lung Cancer\u2014Non-Small Cell Local-Regional\/Small Cell\/Other Thoracic Cancers<br \/>\n<br \/><b>Session Date and Time: <\/b>Monday June 3, 2024 \u2013 1:30 PM \u2013 4:30 PM<\/p>\n<p class=\"bwmarginl1\">\n<b>Abstract: <\/b><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmeetings.asco.org%2Fabstracts-presentations%2F238527&amp;esheet=54014712&amp;newsitemid=20240523437811&amp;lan=en-US&amp;anchor=TPS8129&amp;index=5&amp;md5=5c62919cfcffdd796bdf16fea3cb08b4\" rel=\"nofollow noopener\" shape=\"rect\">TPS8129<\/a><br \/><b>Abstract Title:<\/b> A phase II trial of monalizumab in combination with durvalumab (MEDI4736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART): Hoosier Cancer Research Network LUN21-530 study.<br \/>\n<br \/><b>First Author:<\/b> Hirva Mamdani<br \/>\n<br \/><b>Session Type: <\/b>Poster Session<br \/>\n<br \/><b>Session Title: <\/b>Lung Cancer\u2014Non-Small Cell Local-Regional\/Small Cell\/Other Thoracic Cancers<br \/>\n<br \/><b>Session Date and Time: <\/b>Monday June 3, 2024 \u2013 1:30 PM \u2013 4:30 PM<\/p>\n<p>\n<b>About Innate Pharma<\/b><\/p>\n<p>\nInnate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET<sup>\u00ae<\/sup> (<b>A<\/b>ntibody-based <b>NK<\/b> cell <b>E<\/b>ngager <b>T<\/b>herapeutics) proprietary platform.<\/p>\n<p>\nInnate\u2019s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET<sup>\u00ae<\/sup> multi-specific NK cell engagers to address multiple tumor types.<\/p>\n<p>\nInnate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.<\/p>\n<p>\nHeadquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.<\/p>\n<p>\nLearn more about Innate Pharma at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.innate-pharma.com%2F&amp;esheet=54014712&amp;newsitemid=20240523437811&amp;lan=en-US&amp;anchor=www.innate-pharma.com&amp;index=6&amp;md5=cdbaab507e5b35bbb15c140bf74571e3\" rel=\"nofollow noopener\" shape=\"rect\">www.innate-pharma.com<\/a> and follow us on <a target=\"_blank\" href=\"https:\/\/twitter.com\/InnatePharma\" id=\"smartlink6\" rel=\"nofollow noopener\" shape=\"rect\">X<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Finnate-pharma%2F&amp;esheet=54014712&amp;newsitemid=20240523437811&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=cd88567e07675569935ec4e2cb1859e2\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a>.<\/p>\n<p>\n<b>Information about Innate Pharma shares<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignl bwcellpmargin\">\n<b>ISIN code <\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nFR0010331421<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignl bwcellpmargin\">\n<b>Ticker code <\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nEuronext: IPH Nasdaq: IPHA<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignl bwcellpmargin\">\n<b>LEI<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n9695002Y8420ZB8HJE29<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>Disclaimer on forward-looking information and risk factors<\/b><\/p>\n<p>\nThis press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including \u201cbelieve,\u201d \u201cpotential,\u201d \u201cexpect\u201d and \u201cwill\u201d and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company\u2019s commercialization efforts and the Company\u2019s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the company&#8217;s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (\u201cFacteurs de Risque&#8221;) section of the Universal Registration Document filed with the French Financial Markets Authority (\u201cAMF\u201d), which is available on the AMF website <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amf-france.org&amp;esheet=54014712&amp;newsitemid=20240523437811&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.amf-france.org&amp;index=8&amp;md5=e7a705b07999d913de792f89bb77a730\" rel=\"nofollow noopener\" shape=\"rect\">http:\/\/www.amf-france.org<\/a> or on Innate Pharma\u2019s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including the Company\u2019s Annual Report on Form 20-F for the year ended December 31, 2023, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.<\/p>\n<p>\nThis press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b><span class=\"bwuline\">Investors<\/span><\/b><br \/><b>Innate Pharma<\/b><br \/>Henry Wheeler<br \/>\n<br \/>Tel.: +33 (0)4 84 90 32 88<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#x69;l&#116;&#x6f;&#x3a;H&#101;&#x6e;r&#121;&#x2e;&#x77;h&#101;&#x65;l&#101;&#x72;&#x40;i&#110;&#x6e;&#x61;&#116;&#x65;&#x2d;p&#104;&#x61;&#x72;m&#97;&#x2e;f&#114;\" rel=\"nofollow noopener\" shape=\"rect\">H&#101;&#110;&#x72;&#x79;&#x2e;wh&#101;&#101;&#x6c;&#x65;&#x72;&#64;&#105;&#110;&#110;&#x61;&#x74;&#x65;-&#112;&#104;&#x61;&#x72;&#x6d;a&#46;&#102;&#114;<\/a><\/p>\n<p>\n<b><span class=\"bwuline\">Media Relations<\/span><\/b><br \/><b>NewCap<\/b><br \/>Arthur Rouill\u00e9<br \/>\n<br \/>Tel.: +33 (0)1 44 71 00 15<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;&#105;l&#x74;&#x6f;&#58;i&#x6e;&#x6e;&#97;t&#x65;&#x40;&#110;e&#x77;&#x63;&#97;p&#x2e;&#x65;&#117;\" rel=\"nofollow noopener\" shape=\"rect\">&#x69;&#110;&#x6e;&#97;t&#x65;&#64;n&#x65;&#119;&#x63;&#x61;p&#x2e;&#101;u<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Top line results of TELLOMAK Phase 2 trial in mycosis fungoides confirming promising clinical activity of lacutamab Two posters on IPH6501, Innate\u2019s second generation ANKET\u00ae, for the treatment of relapsed\/refractory CD20-expressing B-cell Non-Hodgkin&#8217;s Lymphoma AstraZeneca to present poster on updated results for monalizumab from Phase 2 stage III unresectable NSCLC trial Monalizumab SCLC Phase 2 &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-59424","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Top line results of TELLOMAK Phase 2 trial in mycosis fungoides confirming promising clinical activity of lacutamab Two posters on IPH6501, Innate\u2019s second generation ANKET\u00ae, for the treatment of relapsed\/refractory CD20-expressing B-cell Non-Hodgkin&#8217;s Lymphoma AstraZeneca to present poster on updated results for monalizumab from Phase 2 stage III unresectable NSCLC trial Monalizumab SCLC Phase 2 ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-24T05:03:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20240523437811\/en\/1245155\/22\/INNATEvertnoirDS.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting\",\"datePublished\":\"2024-05-24T05:03:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\\\/\"},\"wordCount\":886,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240523437811\\\/en\\\/1245155\\\/22\\\/INNATEvertnoirDS.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\\\/\",\"name\":\"Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240523437811\\\/en\\\/1245155\\\/22\\\/INNATEvertnoirDS.jpg\",\"datePublished\":\"2024-05-24T05:03:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240523437811\\\/en\\\/1245155\\\/22\\\/INNATEvertnoirDS.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240523437811\\\/en\\\/1245155\\\/22\\\/INNATEvertnoirDS.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting - Pharma Trend","og_description":"Top line results of TELLOMAK Phase 2 trial in mycosis fungoides confirming promising clinical activity of lacutamab Two posters on IPH6501, Innate\u2019s second generation ANKET\u00ae, for the treatment of relapsed\/refractory CD20-expressing B-cell Non-Hodgkin&#8217;s Lymphoma AstraZeneca to present poster on updated results for monalizumab from Phase 2 stage III unresectable NSCLC trial Monalizumab SCLC Phase 2 ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2024-05-24T05:03:27+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20240523437811\/en\/1245155\/22\/INNATEvertnoirDS.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting","datePublished":"2024-05-24T05:03:27+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\/"},"wordCount":886,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240523437811\/en\/1245155\/22\/INNATEvertnoirDS.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\/","name":"Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240523437811\/en\/1245155\/22\/INNATEvertnoirDS.jpg","datePublished":"2024-05-24T05:03:27+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20240523437811\/en\/1245155\/22\/INNATEvertnoirDS.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20240523437811\/en\/1245155\/22\/INNATEvertnoirDS.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59424","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=59424"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59424\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=59424"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=59424"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=59424"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}